Litcius/Paper detail

<sup>18</sup>F-fluorocholine PET/CT is more sensitive than <sup>11</sup>C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism

Céline Mathey, Caroline Keyzer, Didier Blocklet, Gaëtan Van Simaeys, Nicola Trotta, Simon Lacroix, Bernard Corvilain, Serge Goldman, Rodrigo Moreno‐Reyes

2021Journal of Nuclear Medicine23 citationsDOIOpen Access PDF

Abstract

<b>Purpose:</b> Preoperative molecular imaging is paramount to direct surgery in primary hyperparathyroidism (pHTP). We investigate the diagnostic performance of <sup>18</sup>F-fluorocholine (<sup>18</sup>F-FCH) PET/CT compared to <sup>11</sup>C-methionine (<sup>11</sup>C-MET) PET/CT for the localization of hyperfunctioning parathyroid tissue in patients with pHTP and negative or inconclusive <sup>99m</sup>Tc-sestaMIBI SPECT (MIBI) findings. <b>Materials and Methods:</b> Fifty-eight patients with biochemical evidence of pHTP and negative or inconclusive MIBI were referred for pre-surgical detection and localization of hyperfunctioning parathyroid tissue by <sup>11</sup>C-MET- and <sup>18</sup>F-FCH-PET/CT. The PET/CT results were classified into 3 categories (positive, inconclusive or negative) based on the nodular aspect of tracer uptake and the visualisation of corresponding nodules on CT. The PET/CT results were correlated with the surgical and histopathological findings used as gold standard. <b>Results:</b> Fifty-three patients were included for analysis. <sup>18</sup>F-FCH-PET/CT was positive in 39 patients (74%), inconclusive in 5 (9%) and negative in 9 (17%), compared to 25 (47%), 12 (23%) and 16 (30%) respectively for <sup>11</sup>C-MET-PET/CT. <sup>18</sup>F-FCH localized 11 additional foci (6 positive and 5 inconclusive) compared to <sup>11</sup>C-MET. Twenty-six patients (sex F/M ratio16/10) underwent surgery with resection of 31 lesions (22 adenomas, 6 hyperplastic glands, 3 carcinomas) and 1 normal gland. At follow-up, twenty-one (81%) patients were considered cured after surgery, while 3 (12%) patients had persistence of hypercalcaemia. With inconclusive cases being considered as negative, <sup>18</sup>F-FCH-PET/CT correctly localized 26 lesions in 24/26 (92%) patients compared to 16 lesions in 15/26 (58%) patients localized by <sup>11</sup>C-MET-PET/CT. Per patient-based sensitivity and positive predictive value (PPV) were 96% and 96% for <sup>18</sup>F-FCH and 60% and 94% for <sup>11</sup>C-MET (p&lt;0.0001). Per lesion-based sensitivity and PPV were respectively 84% and 90% for <sup>18</sup>F-FCH vs. 52% and 94% for <sup>11</sup>C-MET (p&lt;0.0001). <b>Conclusion:</b> In the presence of biochemical evidence of pHTP with negative or inconclusive MIBI, <sup>18</sup>F-FCH-PET/CT has a better performance than <sup>11</sup>C-MET-PET/CT for the detection of pathological parathyroid tissue, allowing localization of parathyroid adenoma or hyperplasia in 96% of patients.

Topics & Concepts

MedicinePrimary hyperparathyroidismNuclear medicineHyperparathyroidismPET-CTRadiologyGold standard (test)Parathyroid neoplasmPositron emission tomographyParathyroid adenomaInternal medicineParathyroid Disorders and TreatmentsPancreatic and Hepatic Oncology ResearchNeuroendocrine Tumor Research Advances
<sup>18</sup>F-fluorocholine PET/CT is more sensitive than <sup>11</sup>C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism | Litcius